Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Preferred Dividend Payments (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Preferred Dividend Payments for 4 consecutive years, with $2.6 million as the latest value for Q2 2025.

  • Quarterly Preferred Dividend Payments fell 37.55% to $2.6 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Jun 2025, up 62.45% year-over-year, with the annual reading at $4.6 million for FY2016, 37.75% down from the prior year.
  • Preferred Dividend Payments for Q2 2025 was $2.6 million at Cartesian Therapeutics, down from $4.2 million in the prior quarter.
  • The five-year high for Preferred Dividend Payments was $4.2 million in Q2 2024, with the low at $2.6 million in Q2 2025.